GHK-Cu Glutathione Recovery Blend (GGH)

How GHK-Cu Glutathione Recovery Blend (GGH) works in the body

Dosing evidence

Dose at a Glance

FDA-Approved Dosing There is none There is no FDA-approved GGH fixed-combination product.

There is therefore no approved:

• starting dose

• maintenance dose

• SC dose

• IM dose

• dosing frequency

• cycle length

• titration schedule

Community / Vendor Dosing

The current EvidenceCodex page previously described:

0.5 to 1 mL approximately:

2 to 3 times per week using SC or IM administration.

Evidence Classification Community / vendor protocol Not:

clinically validated GGH dosing

Why mL Alone Is Not Enough

This is one of the most important corrections to the previous page.

Imagine two different GGH products.

Product A 1 mL contains:

• 2 mg GHK-Cu

• 200 mg glutathione

Product B 1 mL contains:

• 10 mg GHK-Cu

• 500 mg glutathione

Taking:

1 mL would mean completely different active doses.

V erdict A GGH protocol should never be interpreted from injection volume alone.

The amount of each ingredient must be provided in:

mg or another appropriate unit per dose.

Frequency at a Glance

Clinical Evidence No clinically established frequency exists for GGH There is no controlled human trial showing that the exact blend should be administered:

• daily

• every other day

• 2x/week

• 3x/week

• weekly

Community Reported schedules include use several times per week.

Evidence Classification Community practice

Best-Supported F requency Unknown

Timing at a Glance

There is no evidence showing the GGH blend works better:

• in the morning

• at night

• fasted

• with food

• before exercise

• after exercise

Evidence V erdict Morning required: No Evening required: No F asted required: No With food required: No Pre-workout required: No Post-workout required: No

Duration / Cycle at a Glance

There is no established clinical GGH cycle.

No evidence shows a biological requirement for:

• 5 days on / 2 days off

• 8-week cycles

• 12-week cycles

• 2-week washouts

• 4-week washouts

Does GGH Need a Receptor Reset?

No evidence supports this GGH is not one conventional receptor agonist.

It is a blend of compounds with different biological roles.

There is no established:

• GGH receptor

• GHK-Cu receptor-reset protocol

• glutathione receptor reset

• required washout period

V erdict No evidence-based receptor-reset logic

Expected Results Timeline

Clinical Timeline Not established There is no controlled human GGH study supporting a timeline such as:

W eek 1: better recovery W eek 2: brighter skin W eek 4: more collagen W eek 8: tissue regeneration These should not be presented as clinical facts.

Community-Reported Timeline Community sources may describe changes in:

• skin appearance

• recovery

• perceived inflammation

• general wellness

over days or weeks.

Important These remain:

anecdotal observations and should not be combined with clinical study timelines from the individual ingredients.

Protocol Logic Check

Protocol Question Verdict Is GGH one standardized molecule? No Is every GGH product the same formula? No Can GGH also mean Gly-Gly-His in scientific literature?

Y es Is Gly-Gly-His research evidence for this blend?

No Human clinical trial of exact GGH blend identified?

No FDA-approved GGH product? No Is 0.5–1 mL meaningful without concentration?

No Is 0.5–1 mL 2–3x/week clinically validated? No Is SC validated for the exact blend? No Is IM validated for the exact blend? No Does GHK-Cu have biological evidence? Y es Is human GHK-Cu evidence stronger topically?

Y es Does glutathione have strong antioxidant biology?

Y es Does that prove injected GGH works? No Can glutathione chemically interact with Cu(II)-GHK?

Y es, in laboratory research Does that automatically prove the finished blend is unstable?

No

Protocol Question Verdict Should compatibility be demonstrated for the exact formula?

Y es Does injectable GHK-Cu have FDA safety concerns?

Y es Have injectable glutathione contamination events occurred?

Y es Is a “Standard Protocol” justified? No Does timing matter? Not established Does GGH require cycling? No evidence Does it need receptor reset? No evidence Are BPC-157 / TB-500 synergies proven? No Can generic vial stability be assumed? No

What Does GHK-Cu Do?

GHK is a naturally occurring tripeptide:

Gly-His-Lys GHK can bind copper to form:

GHK-Cu GHK-Cu has been studied for effects involving:

• extracellular matrix

• collagen

• tissue remodeling

• wound biology

• inflammatory signaling

• oxidative stress

Simple V ersion GHK-Cu appears to act more like a:

tissue-signaling and remodeling molecule than a conventional drug acting through one simple receptor.

Important This is:

GHK-Cu evidence not:

GGH blend evidence

What Does Glutathione Do?

Glutathione is a naturally occurring antioxidant molecule.

It participates in the body’s redox system and helps cells manage oxidative stress.

Simple V ersion Think of glutathione as part of the body’s:

internal antioxidant defense system.

Important Being biologically essential does not prove that:

injecting extra glutathione in a GGH blend improves health in an otherwise healthy person.

Common Research Dose

Cannot be established without the exact formula The previous:

0.5–1 mL figure should not be described as a meaningful dose on its own.

Correct Production W ording Community protocols may describe 0.5–1 mL per injection, but the actual dose depends entirely on the concentration of each active ingredient. No clinically validated GGH dose has been established.

Research Duration / Cycle Length

Clinical Not established Community Variable.

Biological Requirement for Cycling None demonstrated

How Often It Is Used

Clinical Not established Community Often reported several times per week.

Evidence Assessment Community practice only

Community Protocol Comparison

Protocol Dose Route Frequency Evidence Current/older GGH page 0.5–1 mL SC / IM 2–3x weekly Community/vendor Standalone GHK-Cu community protocols Usually expressed in mg SC Variable Community Exact GGH human clinical protocol None established N/A N/A No validated protocol identified Biggest Problem 0.5–1 mL cannot be compared across formulations without knowing mg/mL.

Protocol logic check

No clinically validated universal GGH dose; mL alone does not describe ingredient exposure.

Medical literature and study context

GGH GHK-Cu / Glutathione Blend • Recovery Research • Antioxidant Biology • Skin and Tissue Research

At a Glance

What is GGH?

GGH is a community/vendor blend name , not one standardized drug or one standardized molecule.

The current EvidenceCodex page describes it primarily as a blend involving:

• GHK-Cu

• glutathione

However, some products sold under the name GGH may also contain other ingredients such as:

• histidine

• glycine

• NADH

That means the name GGH alone does not tell you exactly what is in the vial .

Important Before a GGH dose can be interpreted, the exact formulation needs to be known.

Exact Formula For any specific GGH product, confirm:

GHK-Cu: ___ mg/mL Glutathione: ___ mg/mL Histidine: ___ mg/mL, if present Glycine: ___ mg/mL, if present NADH: ___ mg/mL, if present Other ingredients: ___ Why this matters A recommendation such as:

0.5 to 1 mL is only a volume.

It does not tell us how much GHK-Cu, glutathione or any other active ingredient is actually being administered.

Important Name Warning In scientific literature, GGH can also mean Gly-Gly-His , also called glycyl-glycyl-histidine.

That is a separate copper-binding tripeptide.

It is not the same thing as the commercial GGH blend discussed on this page .

Production rule Studies involving:

Gly-Gly-His / GGH peptide should not automatically be used as evidence for:

GHK-Cu + glutathione GGH blends.

How Well Studied Is It?

The individual ingredients have meaningful biological research. The finished GGH blend does not.

This distinction is essential.

GHK-Cu GHK-Cu has research involving:

• skin biology

• collagen and extracellular matrix

• tissue remodeling

• wound healing

• inflammatory signaling

• oxidative stress

Some human evidence exists, but much of the better human evidence is related to:

topical use rather than long-term injection protocols.

Glutathione Glutathione is one of the body’s most important naturally occurring antioxidants.

Its biological role is extremely well established.

It participates in:

• cellular redox balance

• antioxidant defense

• detoxification chemistry

• protection against oxidative stress

But strong glutathione biology does not automatically prove that injecting a GGH blend improves:

• recovery

• skin quality

• energy

• healing

• liver function

• anti-aging outcomes

Exact GGH Blend For the finished injectable blend:

Human clinical efficacy: Not established Human dose-finding: Not established Human pharmacokinetics: Not established Long-term safety: Not established V alidated SC protocol: Not established V alidated IM protocol: Not established Optimal frequency: Not established Same-vial compatibility: Not clinically established Evidence Level GHK-Cu biology: Moderate to strong mechanistic/preclinical evidence Human topical GHK-Cu evidence: Limited but real Injectable GHK-Cu evidence: Limited Glutathione biology: Very strong Exact injectable GGH blend: Very limited Community GGH protocols: Vendor/practice derived

What May It Help With?

GHK-Cu Component GHK-Cu has biological evidence supporting research into:

• extracellular matrix remodeling

• collagen-related processes

• skin repair

• wound biology

• tissue regeneration

• inflammatory signaling

Important That does not mean an injectable GGH blend has been proven to produce the same results.

Glutathione Component Glutathione has strong biological roles involving:

• antioxidant defense

• cellular redox balance

• protection from oxidative stress

Some research also exists involving glutathione and skin pigmentation, but the evidence differs considerably by:

• oral use

• topical use

• IV use

Important Research on one glutathione route should not automatically be applied to another.

What Has the Exact GGH Blend Been Proven to Help With?

No specific clinical benefit has been established I would not describe the exact blend as proven to:

• accelerate wound healing

• improve skin quality

• increase collagen

• lighten skin

• improve athletic recovery

• repair muscles

• repair tendons

• detoxify the liver

• reduce inflammation clinically

• improve mitochondrial function

• increase energy

• slow aging

The ingredients may provide biological reasons to study some of these areas.

That is different from demonstrating the finished blend works clinically.

Bottom Line

GGH is a poorly standardized blend built from ingredients that individually have legitimate biological research.

That does not make the blend itself clinically validated.

The most important things to understand are:

• GGH is not one standardized compound

• different GGH products may contain different ingredients

• dose cannot be interpreted from mL alone

• no validated human GGH dosing protocol has been identified

• component evidence does not prove combination efficacy

• GHK-Cu and glutathione can chemically interact

• injectable GHK-Cu has specific current FDA safety concerns

• injectable glutathione also carries important sterile-product quality risks

Strongest conclusion The exact formula and concentration should be known before any GGH protocol can even be meaningfully evaluated.

Important GHK-Cu Regulatory Distinction

FDA’s current compounding framework treats:

GHK-Cu except injectable routes differently from:

injectable GHK-Cu.

Why?

Injectable formulations raise additional concerns involving:

• sterility

• aggregation

• impurities

• immunogenicity

Important Do not simplify this into:

“GHK-Cu is FDA approved. ” It is not.

And do not simplify it into:

“All GHK-Cu is banned. ” That is also inaccurate.

Important Research Note

Three very different evidence categories are being mixed together when people discuss GGH.

1. GHK-Cu Research This includes legitimate research involving:

• skin

• collagen

• wound healing

• tissue remodeling

But much of the stronger human evidence is:

topical rather than injectable.

2. Glutathione Research Glutathione has strong biological evidence and separate human research.

But evidence differs between:

• oral

• topical

• IV

• other injection routes

3. GGH Blend Evidence This is the weakest category.

The finished combination has not been shown to inherit every proven or proposed benefit of its individual ingredients.

Simple Rule Component evidence is not combination evidence.

Research at a Glance

Approved-Label Evidence None No FDA-approved GGH fixed-combination product exists.

Exact-Blend Human Research V ery limited / not established No controlled exact-blend efficacy program was identified.

GHK-Cu Human Evidence Limited but real Strongest in topical and skin-related research.

Injectable GHK-Cu Evidence Limited Human safety and efficacy evidence remains much thinner than community use suggests.

Glutathione Human Evidence Route dependent Biological role is extremely well established.

Therapeutic evidence depends on:

• indication

• dose

• route

• formulation

Mechanistic Evidence Moderate to strong for the individual components Much weaker for predicting what happens when they are:

mixed and injected together.

Community Evidence Primary source of exact GGH protocols This is much weaker than clinical dose-finding evidence.

Overview

GGH is best understood as:

a community/vendor blend built from separately researched ingredients.

GHK-Cu has a legitimate scientific literature involving tissue and skin biology.

Glutathione has extremely well-established antioxidant and redox biology.

But the most important question is not:

Do GHK-Cu and glutathione each do something biologically?

They clearly do.

The important question is:

Has combining them in this exact injectable formulation been shown to provide a safe and effective clinical benefit?

At present:

that has not been established.

Evidence Strength

Overall Evidence Rating Strong component biology , very weak exact-blend evidence Stronger Evidence F or

• glutathione’s endogenous antioxidant role

• GHK-Cu tissue-remodeling biology

• topical GHK-Cu research

• chemical interaction between glutathione and Cu(II)-GHK

• injectable-product quality concerns

Limited Evidence F or

• injectable GHK-Cu clinical benefit

• injectable glutathione for many wellness/cosmetic claims

Not Established

• exact GGH clinical efficacy

• optimal dose

• optimal frequency

• SC superiority

• IM superiority

• cycling

• receptor reset

• BPC-157 synergy

• TB-500 synergy

• same-vial long-term stability

• generic post-reconstitution expiration

Category

Recovery Blends • Skin / Tissue Research • Antioxidant Research

Compound

GGH Important GGH here refers to a:

GHK-Cu / glutathione-based vendor or community blend

not:

Gly-Gly-His unless specifically stated otherwise.

Compound Type

Multi-ingredient research blend Potential ingredients may include:

• GHK-Cu

• glutathione

• histidine

• glycine

• NADH

depending on the exact product.

V erdict F ormula-dependent

Primary Research Focus

Community GGH products are generally marketed around:

• recovery

• skin

• antioxidant support

• tissue repair

• general regeneration

Evidence Classification These are primarily:

community/vendor research goals rather than established indications for the finished blend.

Regulatory Status

FDA-Approved GGH Product?

No Injectable GHK-Cu FDA has specifically raised safety concerns involving injectable compounded GHK-Cu.

Glutathione Glutathione has separate compounding and sterile-product considerations.

Exact GGH Blend No approved fixed-combination product identified Component regulatory status does not automatically determine:

finished-blend status.

What Studies Have Found

GHK-Cu Research Research supports biological roles involving:

• tissue remodeling

• extracellular matrix

• collagen

• wound biology

• inflammation

• oxidative stress

What This Supports GHK-Cu is a legitimate biologically active compound.

What It Does Not Support A specific:

GGH injection protocol

Glutathione Research

Glutathione is essential to normal redox biology.

Human research also exists around:

• supplementation

• oxidative stress

• pigmentation

What This Supports Glutathione has important biological activity.

What It Does Not Support That:

injecting glutathione as part of GGH creates a proven recovery or anti-aging treatment.

GHK-Cu + Glutathione Chemistry

Laboratory research directly demonstrates interaction between:

Cu(II)-GHK and:

glutathione What This Supports The ingredients can chemically affect each other.

What It Does Not Support That every finished GGH formulation:

• rapidly degrades

• is ineffective

• is unsafe

Correct Interpretation Compatibility must be demonstrated, not assumed.

Independent evidence

Very limited for the finished blend

Ingredient findings do not prove finished-blend efficacy, stability, dosing, or long-term safety.

Storage

Formulation / Stability / Sterility

No Standardized GGH Formulation Exists There is no approved product defining one universal:

• ingredient list

• ingredient ratio

• concentration

• diluent

• pH

• reconstitution method

• storage temperature

• post-reconstitution expiration

Same-Vial Stability

Because GHK-Cu and glutathione can chemically interact:

same-vial stability should not be assumed.

The exact formulation may depend on factors including:

• pH

• excipients

• ingredient ratios

• oxygen exposure

• temperature

• storage time

• copper oxidation state

V erdict Exact formulation data required

Generic 14 / 28-Day Rules

Do not use them There is no universal evidence showing every GGH vial remains:

• chemically stable

• sterile

• potent

for:

14 days or:

28 days after reconstitution.

Simple Rule Use stability information for the exact formulation and product.

Contraindications & cautions

FDA Injectable GHK-Cu Safety Warning

This deserves prominent placement.

FDA has specifically identified injectable GHK-Cu as presenting potential safety concerns.

The concerns include possible:

• immunogenicity

• peptide aggregation

• peptide-related impurities

FDA also notes that human safety information for injectable GHK-Cu is limited.

Important This is not the same as saying:

“GHK-Cu injections are proven dangerous. ” It means the injectable route has unresolved product-quality and immune-response concerns that should not be ignored.

Production W ording FDA has specifically identified injectable GHK-Cu as raising potential immunogenicity concerns related to aggregation and peptide impurities, with limited human safety data.

Injectable Glutathione Product-Quality Risk

FDA has documented serious adverse events after improperly prepared compounded injectable glutathione.

Reported symptoms included:

• nausea

• vomiting

• lightheadedness

• chills

• body aches

One person developed:

• low blood pressure

• difficulty breathing

and required hospital transfer.

FDA testing identified:

excessive bacterial endotoxin in the glutathione material involved.

Critical Distinction These reactions show the danger of:

poor sterile-product quality They should not automatically be described as:

normal pharmacologic side effects of glutathione itself.

Production W ording FDA has documented endotoxin-related reactions from improperly sourced glutathione used in compounded sterile injections. Product quality is therefore a separate safety issue from glutathione’s normal pharmacology .

Safety at a Glance

Exact GGH Blend Long-term safety is unknown No robust clinical safety program was identified for the exact formulation.

Possible Local Effects Community use may involve:

• injection-site discomfort

• redness

• irritation

Classification Plausible / community reported not established exact-blend clinical adverse effects.

Metallic Taste Sometimes discussed around injectable products.

Classification Community / uncertain Do not list as a proven GGH adverse effect.

Lightheadedness Classification Community / uncertain Not established as a characteristic GGH pharmacologic effect.

Headache Classification Nonspecific / uncertain Should not be presented as an established GGH side effect.

Skin Lightening If glutathione affects pigmentation, this would be better described as:

a possible cosmetic effect rather than simply a side effect.

Evidence varies substantially by route.

Copper Accumulation Theoretical concern if copper exposure becomes excessive.

Important Risk cannot be estimated without knowing:

actual GHK-Cu exposure.

Formal Contraindications

None established through an FDA-approved GGH label No approved GGH product exists.

Therefore the page should not create its own formal contraindication list.

Important Cautions

Copper Metabolism Disorders / Wilson Disease GHK-Cu contains copper.

People with disorders of copper handling may require particular caution.

Classification Important biological/clinical caution Not:

formal GGH contraindication Pregnancy / Breastfeeding Safety of the exact blend is not established.

Classification Safety unknown

Concurrent Copper-Altering Therapy Could potentially affect interpretation of copper exposure.

Classification Clinical caution Active Malignancy Do not call active cancer a formal contraindication based only on:

• tissue remodeling

• angiogenesis

• wound-healing biology

The biology is too complex to justify that conclusion.

Classification Uncertain / theoretical caution if retained not:

established contraindication

Commonly Paired With

BPC-157 Often discussed in recovery-oriented community stacks.

V erdict Community combination No controlled human GGH combination evidence.

TB-500 Also commonly paired in tissue-recovery communities.

V erdict Community combination No controlled human GGH combination evidence.

Additional Glutathione This may create duplication if the GGH blend already contains glutathione.

V erdict Check exact formula first GHK-Cu Alone Could also duplicate one of the blend’s main components.

V erdict Potential ingredient overlap

Possible side effects

The supplied chapter does not establish a separate side-effect list for this compound.

Compatibility

GHK-Cu + Glutathione Compatibility

This needs its own section.

Laboratory research has directly shown that:

glutathione can chemically interact with Cu(II)-GHK.

The chemistry involves reduction of the copper center and formation of intermediate copperthiolate species.

What This Means It means the two ingredients are not necessarily chemically invisible to each other when mixed.

What It Does NOT Mean It does not automatically prove that:

• every GGH vial is unstable

• every blend degrades rapidly

• the mixture is unsafe

• all biological activity is lost

Correct Production W ording Glutathione can chemically interact with Cu(II)-GHK in laboratory systems. This does not prove a finished GGH formulation is unstable, but it means same-vial compatibility and stability should be demonstrated for the exact product rather than assumed.

V erdict F ormulation-specific compatibility data needed

Can We Assume the Ingredients Are Synergistic?

No GHK-Cu and glutathione have different biological roles.

That can make the combination sound complementary.

But:

different mechanisms do not automatically equal clinical synergy .

No controlled human study was identified showing that the exact combination produces better outcomes than either component alone.

V erdict Mechanistically interesting, clinically unproven

Route Logic

Subcutaneous Used in community protocols.

Evidence Classification Community route No controlled GGH clinical program establishes SC administration.

Intramuscular Also described in community/vendor use.

Evidence Classification Community route No controlled GGH study establishes IM administration.

Copper Exposure

GHK-Cu contains copper.

That makes total copper exposure potentially relevant.

But the risk cannot be meaningfully evaluated from:

0.5 mL or:

1 mL unless we know how much GHK-Cu is actually in that volume.

T o Estimate Copper Exposure W e Need

• GHK-Cu concentration

• amount injected

• exact molecular form

• frequency

V erdict Copper exposure cannot be quantified from the current mL-only protocol.

Sources

Research Sources

Use clean canonical URLs in production.

1. Current EvidenceCodex GGH Page Evidence type: Current-page audit source https://evidencecodex.pages.dev/library/ghk-cu-glutathione-ggh

2. FDA: Certain Bulk Drug Substances That May Present Significant Safety Risks Evidence type: FDA safety source Supports:

• injectable GHK-Cu concerns

• immunogenicity

• aggregation

• peptide-related impurities

• limited human safety information

https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks 3. FDA 503A Bulk Drug Substances Update Evidence type: FDA regulatory source Supports current distinctions involving:

• GHK-Cu

• injectable GHK-Cu

• glutathione

Use the current FDA 503A bulk-substances document in production.

4. FDA: Injectable Glutathione Sterile-Compounding Alert Evidence type: FDA product-quality safety source Supports:

• endotoxin contamination

• nausea

• vomiting

• lightheadedness

• chills

• body aches

• hypotension

• breathing difficulty

and the distinction between:

contamination risk and:

glutathione pharmacology https://www.fda.gov/drugs/human-drug-compounding/fda-highlights-concerns-using-dietary-ingredient-glutathione-compound-sterile-injectables

5. Ufnalska et al. 2021 Intermediate Cu(II)-Thiolate Species in the Reduction of Cu(II)GHK by Glutathione Evidence type: Laboratory chemistry research Supports:

• direct chemical interaction between Cu(II)-GHK and glutathione

• copper reduction chemistry

• need to avoid assuming inert same-vial compatibility

https://pubmed.ncbi.nlm.nih.gov/34781677/ 6. Pickart et al.

Regenerative and Protective Actions of the GHK-Cu Peptide Evidence type: GHK-Cu biological review Supports:

• tissue-remodeling biology

• wound-related mechanisms

• collagen / extracellular-matrix rationale

https://pubmed.ncbi.nlm.nih.gov/29986520/ 7. GHK-Cu / GHK Anti-Aging Review Evidence type: Biological/mechanistic review Useful for separating:

GHK-Cu biology from:

exact-blend evidence https://pubmed.ncbi.nlm.nih.gov/35083444/ 8. PeptideDosingProtocols: GHK-Cu Evidence type: Community / evidence-reconciliation source Useful for documenting:

• current GHK-Cu community practice

• topical versus injectable evidence distinction

https://www.peptidedosingprotocols.com/protocol/ghk-cu 9. PeptideDosages: GHK-Cu Evidence type: Community dosing source Useful for standalone GHK-Cu community dose examples.

It does not validate the exact GGH blend.

https://peptidedosages.com/single-peptide-dosages/ghk-cu-100-mg-vial-dosage-protocol/ 10. Glutathione Skin-Lightening Systematic Review Evidence type: Human evidence review Useful for separating:

• oral

• topical

• IV

glutathione evidence.

https://pubmed.ncbi.nlm.nih.gov/39444151/ 11. PeptidePlotter: GGH Evidence type: Community/vendor blend documentation Useful for documenting that one current product called GGH contains:

• GHK-Cu

• glutathione

• histidine

• glycine

• NADH

It is not clinical efficacy evidence.

https://peptideplotter.com/compounds/ggh

Final Takeaway

GGH should not be presented as a standardized injectable therapy .

It is a blend name used in the research/community market.

Its ingredients may have legitimate biological research individually, especially:

GHK-Cu and:

glutathione But there is a major difference between:

“These ingredients each have biological effects. ” and:

“This exact combined injection has been clinically shown to work. ” The second claim has not been established.

The biggest production rules are:

Do not call 0.5–1 mL a meaningful dose unless the exact mg/mL of every active ingredient is shown.

Replace “Standard Protocol” with “Community / V endor Protocol Example. ” Do not treat separate GHK-Cu or glutathione studies as clinical evidence for GGH.

Clearly distinguish the commercial GGH blend from Gly-Gly-His, which is also abbreviated GGH in scientific literature.

Keep the GHK-Cu + glutathione chemical-interaction warning, but do not claim this proves the finished blend is unstable or unsafe.

Prominently include FDA’s injectable GHK-Cu concerns involving immunogenicity , aggregation and peptide impurities.

Keep endotoxin-contaminated glutathione reactions under productquality risk rather than presenting them as normal glutathione side effects.

Use “Commonly Paired With,” not “synergistic,” for BPC-157, TB-500 or similar compounds.

Do not create formal GGH contraindications when no approved GGH label exists.

Do not use generic 14-day or 28-day stability rules. The exact formulation needs its own evidence.

This version is now the one I would consider publish-ready, with one remaining product-specific field to fill whenever you know the actual Navaro GGH formulation: the exact ingredient amounts/concentrations.

Navaro Compounds.pdf, pages 299–330.